BioPorto Showcases Innovations in Kidney Diagnostics
BioPorto is excited to engage with healthcare professionals at the upcoming Association for Diagnostics & Laboratory Medicine meeting, where the spotlight will be on Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Acute Kidney Injury (AKI). This premier event gathers key players in laboratory medicine to focus on critical advancements that can shape the future of patient care.
Understanding the Importance of AKI in Clinical Settings
Acute kidney injury represents a significant challenge in the medical field. As clinicians grapple with updating the estimated glomerular filtration rate calculation, the implications of AKI on patient pathways have become clearer. The transition from AKI to Chronic Kidney Disease (CKD) is a critical area that medical professionals must monitor closely.
Special Sessions Highlighting NGAL's Role
At the conference, one session will feature Dr. Nazim Bithi from Baylor College of Medicine, emphasizing the potential of NGAL as a biomarker for early detection of AKI in pediatric patient populations. Traditional diagnostic methods often fail to recognize AKI until the condition has progressed, leading to increased risks for patients. By concentrating on NGAL, healthcare providers can intervene sooner, ultimately improving outcomes.
Dr. Bithi's session aims to outline NGAL's efficacy compared to other markers like serum creatinine and cystatin C, illustrating the advantages of monitoring NGAL levels following kidney stress.
Next-Generation Biomarkers and Their Impact
The second highlighted session will exploratively discuss next-generation biomarkers that can revolutionize early detection and diagnosis of AKI. This presentation, led by Raj Pandya from the University of Utah, promises to enlighten attendees on innovative strategies to enhance AKI management.
BioPorto's Presence at the Conference
BioPorto will have a prominent presence at Booth #5327, where we will present our flagship product, ProNephro AKI™ (NGAL). This product has received FDA clearance for assessing the risk of moderate to severe (stage 2/3) AKI in ICU patients ranging from 3 months to 21 years of age. Our team is eager to connect with laboratory directors, clinical chemistry managers, and medical professionals to showcase the benefits of incorporating NGAL testing into their practices.
Furthermore, this conference will be an opportunity for BioPorto to discuss business impacts with our global partners and collaborators. As we evaluate the ongoing U.S. studies for adult populations, we anticipate exciting developments in AKI diagnostics.
Looking Ahead: Education and Resources
As part of the commitment to continuous education, BioPorto emphasizes the importance of sharing knowledge regarding new approaches to AKI diagnostics. The Association for Diagnostics & Laboratory Medicine continuously supports educational efforts, which include access to recorded sessions. One such highlighted presentation includes insights from Dr. Prasad Devarajan on NGAL's role in AKI, which has garnered interest and is expected to maintain momentum through 2026.
For those wishing to stay informed about the latest updates on AKI and NGAL, opportunities are available to sign up for notifications concerning new guidelines and product innovations.
Meet the Team Behind BioPorto
Jennifer Zonderman, our Senior Vice President of Global Marketing and Commercialization, expresses the excitement about meeting industry peers and partners at such a prestigious gathering. She emphasizes the vital role of laboratory professionals in enhancing patient care and looks forward to strategizing with collaborators to advance kidney health diagnostics.
Contact Details:
For more information about BioPorto, feel free to reach out to:
Jennifer Zonderman, BioPorto, +1 617 694 2918, jmz@bioporto.com
Hanne Søgaard Foss, BioPorto, Head of Investor Relations, +45 4529 0000, investor@bioporto.com
Frequently Asked Questions
What is the focus of the Association for Diagnostics & Laboratory Medicine meeting?
The meeting emphasizes advancements in kidney diagnostics, particularly NGAL and Acute Kidney Injury (AKI).
What role does NGAL play in diagnosing AKI?
NGAL is a biomarker that allows for early detection of AKI, enhancing timely patient management and outcomes.
Where can I find BioPorto at the conference?
BioPorto will be stationed at Booth #5327, showcasing ProNephro AKI™ (NGAL).
Who are the key speakers at the conference covering NGAL?
Dr. Nazim Bithi and Dr. Raj Pandya will present significant findings related to NGAL at the event.
How can I sign up for notifications related to AKI guidelines?
Interested individuals can visit BioPorto’s website to register for updates concerning new guidelines and product news.
